| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 06/29/2006 | WO2006067150A1 Oral immediate release formulation of a poorly watersoluble active substance |
| 06/29/2006 | WO2006066949A1 Compositions comprising an epothilone and production methods |
| 06/29/2006 | WO2006066891A2 Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
| 06/29/2006 | WO2006066868A2 Sustained release formulation comprising bisphosphonate |
| 06/29/2006 | WO2006066643A1 Esters of choline and fatty acids with bactericide activity and products containing such esters for cosmetic or dermo-pharmaceutical products |
| 06/29/2006 | WO2006066637A1 Use of cyclodextrin complexes containing lipoic acid |
| 06/29/2006 | WO2006066500A1 The preparation process of quinazoline derivatives and application for the manufacture for the treatment of tumor disease |
| 06/29/2006 | WO2006066399A1 Tablet formulation for sustained drug-release |
| 06/29/2006 | WO2006041641A3 Therapeutic agents with decreased toxicity |
| 06/29/2006 | WO2006039667A3 Water-based delivery systems |
| 06/29/2006 | WO2006036834A3 MODIFIED Fc MOLECULES |
| 06/29/2006 | WO2005118782A3 Methods of promoting cardiac cell proliferation |
| 06/29/2006 | WO2005112886A3 Methods and articles for the delivery of therapeutic agents |
| 06/29/2006 | WO2005110277A3 Carboxylated polysaccharides and method of preparation and use |
| 06/29/2006 | WO2005107730A3 Cysteamines for treating complications of hypercholesterolemia and diabetes |
| 06/29/2006 | WO2005051418A3 Pharmaceutical formulations for the sustained release of interleukins and therapeutic applications thereof |
| 06/29/2006 | WO2005010164A3 Nucleic acid biomaterials and methods of formation and use |
| 06/29/2006 | WO2003106644A3 Stabilized anti-respiratory syncytial virus (rsv) antibody formulations |
| 06/29/2006 | US20060142478 Carboxyalkyl cellulose polymer network |
| 06/29/2006 | US20060142477 Method for making sulfoalkylated cellulose polymer network |
| 06/29/2006 | US20060142382 Skin lightening composition |
| 06/29/2006 | US20060142374 Crystal for oral solid drug and oral solid drug for dysuria treatment containing the same |
| 06/29/2006 | US20060142230 Double-stranded ribonucleic acid molecules having ribothymidine |
| 06/29/2006 | US20060142229 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof |
| 06/29/2006 | US20060142225 siNA molecule comprising a double-stranded structure that down-regulates expression of cyclin dependent kinase-2 (CDK2) , wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 06/29/2006 | US20060142224 Modulation of immunostimulatory activity of immunostimulatory oligonucleotide analogs by positional chemical changes |
| 06/29/2006 | US20060142169 Ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers |
| 06/29/2006 | US20060141597 Valency platform molecules comprising aminooxy groups |
| 06/29/2006 | US20060141567 For selective modulation of leukocyte function, which is useful in a variety of inflammatory and autoimmune diseases, or in therapy of infections |
| 06/29/2006 | US20060141545 Cancer treatment kits using antibodies to aminophospholipids |
| 06/29/2006 | US20060141482 Method and multicomponent conjugates for treating cancer |
| 06/29/2006 | US20060141080 Extracting crushed plant material Cuminum cyminum with water or 50% aqueous alcoholic solvent; extracting a portion of the aqueous extract with n-butanol, separating -butanol layer and an aqueous layer, evaporating, and freeze drying the aqueous layer |
| 06/29/2006 | US20060141052 Drug microparticles |
| 06/29/2006 | US20060141051 Drug microparticles |
| 06/29/2006 | US20060141050 Drug microparticles |
| 06/29/2006 | US20060141049 Suspended in viscosity modifier (hyaluronic acid) and carrier; sustained release; treating macular edem |
| 06/29/2006 | US20060141042 Hollow nanoparticle having modified cysteine residue and drug with the use thereof |
| 06/29/2006 | US20060141019 Liposome |
| 06/29/2006 | US20060141007 Agent with a retarded release of substances |
| 06/29/2006 | US20060141003 Antifungal paints and coatings |
| 06/29/2006 | US20060141002 Coated implants and methods of coating |
| 06/29/2006 | US20060140991 Pharmaceutical preparations having an improved solubility |
| 06/29/2006 | US20060140986 Anesthetic composition for topical administration |
| 06/29/2006 | US20060140981 Intranasal delivery of pneumococcal polysaccharide vaccines |
| 06/29/2006 | US20060140966 Immunogenic acute phase protein-antigenic molecule complexes and fusion proteins |
| 06/29/2006 | US20060140952 Tumour necrosis factor binding ligands |
| 06/29/2006 | US20060140951 Tumour necrosis factor binding ligands |
| 06/29/2006 | US20060140941 Growth differentiation factor-3 |
| 06/29/2006 | US20060140928 Use of heparinases to decrease inflammatory response |
| 06/29/2006 | US20060140907 Central airway administration for systemic delivery of therapeutics |
| 06/29/2006 | US20060140904 Random alkylene oxide copolymers for medical and surgical utilities |
| 06/29/2006 | US20060140889 Affinity proteins for controlled application of cosmetic substances |
| 06/29/2006 | US20060140858 Drug pre-targeting by means of bi-specific antibodies and hapten constructs comprising a carrier peptide and the active agent(s) |
| 06/29/2006 | US20060140847 Method for introducing functional material into organic nanotube |
| 06/29/2006 | DE19950686B4 Multifunktionelle Spacer Multifunctional Spacer |
| 06/29/2006 | DE102004062468A1 Composition (for vaginal application), useful for influencing the genitalia of the mammalian offsprings, comprises thickeners |
| 06/29/2006 | DE10038110B4 Pharmazeutische Zusammensetzungen Pharmaceutical compositions |
| 06/29/2006 | CA2595517A1 Drug carrier and drug carrier kit for inhibiting fibrosis |
| 06/29/2006 | CA2592474A1 Prostaglandin f2.alpha. derivative-containing product |
| 06/29/2006 | CA2592249A1 Binding proteins specific for human matriptase |
| 06/29/2006 | CA2592030A1 Solid dosage form comprising proton pump inhibitor and suspension made thereof |
| 06/29/2006 | CA2592006A1 Conjugates of insulin-like growth factor-1 (igf-1) and poly(ethylene glycol) |
| 06/29/2006 | CA2591997A1 Compositions comprising an epothilone and production methods |
| 06/29/2006 | CA2591806A1 Tablet formulation for sustained drug-release |
| 06/29/2006 | CA2591744A1 Stable non-dihydrate azithromycin oral suspensions |
| 06/29/2006 | CA2591233A1 Stabilized polymeric thiol reagents |
| 06/29/2006 | CA2591129A1 Treatment of inflammatory diseases |
| 06/29/2006 | CA2590936A1 Combination therapy for b cell disorders |
| 06/29/2006 | CA2590848A1 Oral immediate release formulation of a poorly water-soluble active substance |
| 06/29/2006 | CA2585116A1 Sustained release formulation comprising bisphosphonate |
| 06/28/2006 | EP1674474A1 Cyclic maltosyl maltose, cyclic maltosyl maltose synthase, method of producing the same and use thereof |
| 06/28/2006 | EP1674113A1 Conjugates of insulin-like growth factor-1 (IGF-1) and poly(ethylene glycol) |
| 06/28/2006 | EP1674099A1 Therapeutic combination of amlodipine and benazepril / benazeprilat |
| 06/28/2006 | EP1674098A1 Stable and tolerable parental formulations of highly reactive organic drug substances with low or no solubility in water |
| 06/28/2006 | EP1674095A1 Phototherapy compositions |
| 06/28/2006 | EP1674094A1 Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt |
| 06/28/2006 | EP1674093A1 Method of controlling particle size of retinoic acid nanoparticles coated with polyvalent metal inorganic salt and nanoparticles obtained by the controlling method |
| 06/28/2006 | EP1674088A1 Jelly preparation containing biguanide medicine |
| 06/28/2006 | EP1674086A2 Shape-retentive hydrogel particle aggregates and their uses |
| 06/28/2006 | EP1674084A2 Extended release oral dosage composition |
| 06/28/2006 | EP1674083A1 Tablet quickly disintegrating in oral cavity |
| 06/28/2006 | EP1674079A2 Pressurised metered dose inhalers (MDI) |
| 06/28/2006 | EP1674078A2 Fast dissolving orally consumable filsm containing an ion exchange resin as a taste masking agent |
| 06/28/2006 | EP1674068A1 Dermal penetration enhancers and drug delivery systems involving same |
| 06/28/2006 | EP1673449A2 Immunogenic composition and method of developing a vaccine based on fusion protein |
| 06/28/2006 | EP1673448A2 Immunogenic compostion and method of developing a vaccine based on psoralen inactivated hiv |
| 06/28/2006 | EP1673447A1 Immunogenic composition and method of developing a vaccine based on portions of the hiv matrix protein |
| 06/28/2006 | EP1673387A1 Il-21 derivatives |
| 06/28/2006 | EP1673108A2 Methods and compositions for ultrasound imaging of apoptosis |
| 06/28/2006 | EP1673099A1 Compositions and methods for inhibiting cell senescence and hyperproliferative disorders |
| 06/28/2006 | EP1673079A1 Pharmaceutical composition comprising 5-methyl-2-(2'-chloro-6'-fluoroanilino)phenylacetic acid |
| 06/28/2006 | EP1673067A1 Monodispersed solid lipid particle compositions |
| 06/28/2006 | EP1673065A1 Microemulsions of retinoids, and pharmaceutical compositions containing them |
| 06/28/2006 | EP1673063A1 Transdermal pharmaceutical composition |
| 06/28/2006 | EP1673062A2 Antimicrobial compositions and methods |
| 06/28/2006 | EP1672978A2 Cobalamin conjugates for anti-tumor therapy |
| 06/28/2006 | EP1594488B1 Stabilized pharmaceutical compositions of safingol and methods of using the same |
| 06/28/2006 | EP1507874A4 Compositions and processes for inhibiting gene expression using polynucleotides |
| 06/28/2006 | EP1409034B1 Topical pharmaceutical formulation |
| 06/28/2006 | EP1372694B1 Liposome targeting of matrix metalloproteinase inhibitors |